Compare · MVIS vs TMO
MVIS vs TMO
Side-by-side comparison of MicroVision Inc. (MVIS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MVIS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $225.41B, about 487.1x MVIS ($462.8M).
- Over the past year, MVIS is down 43.9% and TMO is up 11.5% - TMO leads by 55.3 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- TMO has more recent analyst coverage (25 ratings vs 2 for MVIS).
- Company
- MicroVision Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.65+1.29%
- $469.57+0.63%
- Market cap
- $462.8M
- $225.41B
- 1M return
- -5.06%
- -4.31%
- 1Y return
- -43.85%
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- News (4w)
- 6
- 6
- Recent ratings
- 2
- 25
MicroVision Inc.
MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was incorporated in 1993 and is headquartered in Redmond, Washington.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MVIS
- SEC Form S-3 filed by MicroVision Inc.
- MicroVision Accelerates Revenue Growth in Industrial Autonomy Through Lidar 2.0 Execution
- Amendment: MicroVision Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- MicroVision Launches Global Partner and Reseller Program to Accelerate Adoption of Lidar 2.0
- SEC Form 4 filed by Hrynewich Stephen
- MicroVision Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Devos Glen W.
- Amendment: SEC Form SCHEDULE 13G/A filed by MicroVision Inc.
- Executive Vice Chair Biddiscombe Simon was granted 93,950 shares, increasing direct ownership by 32% to 385,249 units (SEC Form 4)
- Director Herbst Jeffrey A was granted 28,185 shares, increasing direct ownership by 12% to 258,912 units (SEC Form 4)
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S